Jill M. Taymans
Known title: VP Finance, CFOCIK: 0001261283
Associated companies
Transaction History
| CCEL | ▲ Buy | Option Exercise | 7,500 | $23K | 5/28/2026 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 7,500 | $23K | 5/28/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates
Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates. Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.